MX2021011746A - Formulacion de combinacion triple de dosis baja. - Google Patents
Formulacion de combinacion triple de dosis baja.Info
- Publication number
- MX2021011746A MX2021011746A MX2021011746A MX2021011746A MX2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A MX 2021011746 A MX2021011746 A MX 2021011746A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- low dose
- combination formulation
- triple combination
- biguanide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/364,063 US11033544B2 (en) | 2019-03-25 | 2019-03-25 | Low-dose triple combination formulation |
| PCT/IB2020/000214 WO2020194052A1 (en) | 2019-03-25 | 2020-03-25 | Low-dose triple combination formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011746A true MX2021011746A (es) | 2021-10-22 |
Family
ID=72606637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011746A MX2021011746A (es) | 2019-03-25 | 2020-03-25 | Formulacion de combinacion triple de dosis baja. |
| MX2024013504A MX2024013504A (es) | 2019-03-25 | 2021-09-24 | Formulacion de combinacion triple de dosis baja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013504A MX2024013504A (es) | 2019-03-25 | 2021-09-24 | Formulacion de combinacion triple de dosis baja |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11033544B2 (https=) |
| EP (1) | EP3946344A4 (https=) |
| JP (1) | JP7586830B2 (https=) |
| KR (1) | KR20220004027A (https=) |
| CN (2) | CN113924096A (https=) |
| AU (2) | AU2020247542A1 (https=) |
| BR (1) | BR112021018994A2 (https=) |
| CA (1) | CA3134800A1 (https=) |
| MX (2) | MX2021011746A (https=) |
| TW (2) | TW202102209A (https=) |
| WO (1) | WO2020194052A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
| KR102853692B1 (ko) * | 2021-07-08 | 2025-09-02 | 한미약품 주식회사 | 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제 |
| EP4415723A4 (en) * | 2021-10-12 | 2025-09-03 | Unison Pharmaceuticals Pvt Ltd | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN |
| TR2023001202A1 (tr) * | 2023-02-02 | 2024-08-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇ |
| KR20260000968A (ko) * | 2024-06-26 | 2026-01-05 | 주식회사 종근당 | 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| BRPI1008560B1 (pt) * | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| EP3142661B1 (en) * | 2014-05-16 | 2021-10-06 | Astrazeneca AB | Method for suppressing glucagon secretion of an sglt2 inhibitor |
| US20160067217A1 (en) * | 2014-09-09 | 2016-03-10 | ARKAY Therapeutics, LLC | Metabolic syndrome treatment |
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
-
2019
- 2019-03-25 US US16/364,063 patent/US11033544B2/en active Active
-
2020
- 2020-03-25 MX MX2021011746A patent/MX2021011746A/es unknown
- 2020-03-25 CA CA3134800A patent/CA3134800A1/en active Pending
- 2020-03-25 KR KR1020217033517A patent/KR20220004027A/ko active Pending
- 2020-03-25 TW TW109110099A patent/TW202102209A/zh unknown
- 2020-03-25 CN CN202080038969.1A patent/CN113924096A/zh active Pending
- 2020-03-25 TW TW114106241A patent/TW202545526A/zh unknown
- 2020-03-25 AU AU2020247542A patent/AU2020247542A1/en not_active Abandoned
- 2020-03-25 BR BR112021018994A patent/BR112021018994A2/pt unknown
- 2020-03-25 WO PCT/IB2020/000214 patent/WO2020194052A1/en not_active Ceased
- 2020-03-25 CN CN202411820468.5A patent/CN119607213A/zh active Pending
- 2020-03-25 EP EP20779606.1A patent/EP3946344A4/en active Pending
- 2020-03-25 JP JP2021556884A patent/JP7586830B2/ja active Active
-
2021
- 2021-05-11 US US17/317,614 patent/US20210260056A1/en not_active Abandoned
- 2021-09-24 MX MX2024013504A patent/MX2024013504A/es unknown
- 2021-11-15 US US17/527,087 patent/US20220226317A1/en not_active Abandoned
- 2021-11-15 US US17/527,084 patent/US20220226315A1/en not_active Abandoned
- 2021-11-15 US US17/527,085 patent/US20220226316A1/en not_active Abandoned
-
2025
- 2025-09-03 AU AU2025226705A patent/AU2025226705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7586830B2 (ja) | 2024-11-19 |
| US20220226317A1 (en) | 2022-07-21 |
| US20200306246A1 (en) | 2020-10-01 |
| CN119607213A (zh) | 2025-03-14 |
| US20220226315A1 (en) | 2022-07-21 |
| US20220226316A1 (en) | 2022-07-21 |
| WO2020194052A1 (en) | 2020-10-01 |
| KR20220004027A (ko) | 2022-01-11 |
| MX2024013504A (es) | 2024-12-06 |
| EP3946344A4 (en) | 2022-12-28 |
| TW202545526A (zh) | 2025-12-01 |
| CA3134800A1 (en) | 2020-10-01 |
| TW202102209A (zh) | 2021-01-16 |
| AU2020247542A1 (en) | 2021-11-11 |
| EP3946344A1 (en) | 2022-02-09 |
| US11033544B2 (en) | 2021-06-15 |
| BR112021018994A2 (pt) | 2022-02-08 |
| JP2022529208A (ja) | 2022-06-20 |
| US20210260056A1 (en) | 2021-08-26 |
| CN113924096A (zh) | 2022-01-11 |
| AU2025226705A1 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011746A (es) | Formulacion de combinacion triple de dosis baja. | |
| CL2023003489A1 (es) | Análogos triazolo-pirimidina para tratamiento de enfermedades relacionadas con inhibición helicasa recq del síndrome de werner | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX2021011745A (es) | Formulacion de combinacion triple baja en dosis. | |
| CL2023000167A1 (es) | Péptidos funcionalizados como agentes antivirales | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| MX2021004431A (es) | Procesos novedosos. | |
| GEAP202316298A (en) | Highly active compounds against covid-19 | |
| MX2019012884A (es) | Terapia de combinacion. | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| NO20091938L (no) | 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2004000437A1 (es) | Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| AR062779A1 (es) | Tratamiento de la esclerosis multiple (em) |